Pulmonary Delivery of Nanoparticles of Insoluble, Iodinated CT x-ray coNtrast Agents to Lung Draining Lymph Nodes in Dogs

McIntire, Gregory L.; Bacon, Edward R.; Toner, John L.; Cornacoff, Joel B.; Losco, Patricia E.; Illig, Kathleen J.; Nikula, Kristen J.; Muggenburg, Bruce A.; Ketai, Loren H.

doi:10.1021/js980060r

Cited by 39 publications

(26 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Research essentially focuses [213,214] on the incorporation of iodinated organic compounds into NPs, with designs ranging from emulsions, [215][216][217][218] liposomes, [214,[219][220][221][222][223] and lipoproteins, [224,225] to insoluble nano objects, [214,[226][227][228] and polymeric NPs, [215,[229][230][231][232][233]; many of them have been successfully applied in vivo [28,56]. The purpose of these nanomaterials is to locally increase iodine concentrations, Some multimodal nanoparticles were doped with an iodinated compound and used to enhance X-ray contrast [216,224,234,235] as discussed in later on in the review.…”

Section: Iodinated Nanoparticlesmentioning

confidence: 99%

Functionalized nanomaterials: their use as contrast agents in bioimaging: mono- and multimodal approaches

Trequesser¹,

Seznec²,

Delville³

2016

Nano Online

View full text Add to dashboard Cite

The successful development of nanomaterials illustrates the considerable interest in the development of new molecular probes for medical diagnosis and imaging. Substantial progress was made in synthesis protocol and characterization of these materials whereas toxicological issues are sometimes incomplete. Nanoparticle-based contrast agents tend to become efficient tools for enhancing medical diagnostics and surgery for a wide range of 2 imaging modalities. Multimodal nanoparticles (NPs) are much more efficient than conventional molecular-scale contrast agents. They provide new abilities for in vivo detection and enhanced targeting efficiencies through longer circulation times, designed clearance pathways, and multiple binding capacities. Properly protected, they can safely be used for the fabrication of various functional systems with targeting properties, reduced toxicity and proper removal from the body. This review mainly describes the advances in the development of mono-to multimodal NPs and their in vitro and in vivo relevant biomedical applications ranging from imaging and tracking to cancer treatment. Besides specific applications for classical imaging, (MRI, PET, CT, US, PAI) are also mentioned less common imaging techniques such as terahertz molecular imaging (THMI) or ion beam analysis (IBA).Perspectives on multimodal theranostic NPs and their potential for clinical advances are also mentioned.

show abstract

Section: Iodinated Nanoparticlesmentioning

confidence: 99%

Functionalized nanomaterials: their use as contrast agents in bioimaging: mono- and multimodal approaches

Trequesser¹,

Seznec²,

Delville³

2016

Nano Online

View full text Add to dashboard Cite

show abstract

“…74,76 Further, alveolar clearance of drug particles up to a certain diameter (200 nm) involves the lymphatic system. 71,78,79 This renders drug targeting with SLNs feasible, and several studies have been done involving delivery of SLNs in patients with lung cancer via nebulization and gene therapy. 72,80 Videira et al formulated an SLNs system incorporating paclitaxel, which is widely used in the treatment of non-small cell lung cancer.…”

Section: Pulmonary Route For Lymphatic Delivery Of Slnsmentioning

confidence: 99%

“…Uptake of SLNs into the lymphatic system was demonstrated earlier by Videira et al using radiolabeled SLNs whereas other researchers used a computed tomography contrast agent. 71,79 Both studies demonstrated that biodistribution of SLNs occurs primarily via the lymphatic system rather than by the blood circulation. Thus, specific delivery of cytotoxic drugs via inhalation using SLNs could be a promising option for chemotherapy in the future.…”

Section: Pulmonary Route For Lymphatic Delivery Of Slnsmentioning

confidence: 99%

Advanced drug delivery to the lymphatic system: lipid-based nanoformulations

Khan

Mudassir²,

Mohtar³

et al. 2013

IJN

140

View full text Add to dashboard Cite

Abstract:The delivery of drugs and bioactive compounds via the lymphatic system is complex and dependent on the physiological uniqueness of the system. The lymphatic route plays an important role in transporting extracellular fluid to maintain homeostasis and in transferring immune cells to injury sites, and is able to avoid first-pass metabolism, thus acting as a bypass route for compounds with lower bioavailability, ie, those undergoing more hepatic metabolism. The lymphatic route also provides an option for the delivery of therapeutic molecules, such as drugs to treat cancer and human immunodeficiency virus, which can travel through the lymphatic system. Lymphatic imaging is useful in evaluating disease states and treatment plans for progressive diseases of the lymph system. Novel lipid-based nanoformulations, such as solid lipid nanoparticles and nanostructured lipid carriers, have unique characteristics that make them promising candidates for lymphatic delivery. These formulations are superior to colloidal carrier systems because they have controlled release properties and provide better chemical stability for drug molecules. However, multiple factors regulate the lymphatic delivery of drugs. Prior to lymphatic uptake, lipid-based nanoformulations are required to undergo interstitial hindrance that modulates drug delivery. Therefore, uptake and distribution of lipidbased nanoformulations by the lymphatic system depends on factors such as particle size, surface charge, molecular weight, and hydrophobicity. Types of lipid and concentration of the emulsifier are also important factors affecting drug delivery via the lymphatic system. All of these factors can cause changes in intermolecular interactions between the lipid nanoparticle matrix and the incorporated drug, which in turn affects uptake of drug into the lymphatic system. Two lipid-based nanoformulations, ie, solid lipid nanoparticles and nanostructured lipid carriers, have been administered via multiple routes (subcutaneous, pulmonary, and intestinal) for targeting of the lymphatic system. This paper provides a detailed review of novel lipid-based nanoformulations and their lymphatic delivery via different routes, as well as the in vivo and in vitro models used to study drug transport in the lymphatic system. Physicochemical properties that influence lymphatic delivery as well as the advantages of lipid-based nanoformulations for lymphatic delivery are also discussed.

show abstract

“…Risk assessment of nanomaterials is, however, mainly done using animals, like rats (Kapp et al, 2004;Geiser et al, 2005;Kuempel et al, 2006), mice (Vaughn et al, 2006), cats (Bice et al, 2000), as well as dogs (McIntire et al, 1998;Bice et al, 2000;Wellenius et al, 2003).…”

Section: Particle Incubationmentioning

confidence: 99%

The biological and ethical basis of the use of human embryonic stem cells for in vitro test systems or cell therapy

Leist

Bremer²,

Brundin³

et al. 2008

ALTEX

View full text Add to dashboard Cite

Pulmonary Delivery of Nanoparticles of Insoluble, Iodinated CT x-ray coNtrast Agents to Lung Draining Lymph Nodes in Dogs

Cited by 39 publications

References 11 publications

Functionalized nanomaterials: their use as contrast agents in bioimaging: mono- and multimodal approaches

Functionalized nanomaterials: their use as contrast agents in bioimaging: mono- and multimodal approaches

Advanced drug delivery to the lymphatic system: lipid-based nanoformulations

The biological and ethical basis of the use of human embryonic stem cells for in vitro test systems or cell therapy

Contact Info

Product

Resources

About